Nature Communications (Jan 2021)

Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML

  • Toshihiko Oki,
  • Francois Mercier,
  • Hiroki Kato,
  • Yookyung Jung,
  • Thomas O. McDonald,
  • Joel A. Spencer,
  • Michael C. Mazzola,
  • Nick van Gastel,
  • Charles P. Lin,
  • Franziska Michor,
  • Toshio Kitamura,
  • David T. Scadden

DOI
https://doi.org/10.1038/s41467-020-20491-8
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 13

Abstract

Read online

The role of mTORC1 in AML has not yet been proven due to the mixed results of its inhibitors in clinical trials. Here the authors show the real-time dynamics of the mTORC1 pathway in association with AML growth and response to chemotherapy with fluorescent markers, providing guidance for timed intervention with pathway-specific inhibitors.